A novel nucleus-penetrating peptide (Cy5p53Tet) specifically targets mutant p53 protein in triple negative breast cancer cells, enabling tumor visualization within 12 minutes of injection in mice — with potential for fluorescence-guided surgery.
Tumor visible in 12 minutesAfter injection in tumor-bearing mice, Cy5p53Tet accumulated in mutant p53-expressing TNBC tumors within 12 minutes — a rapid time frame suitable for intraoperative imaging during breast cancer surgery.
What the researchers found
Cy5p53Tet — a p53 tetramerization domain peptide conjugated to Cy5 fluorophore — showed higher nuclear uptake in TNBC MDA-MB-468 cells (with mutant p53 R273H) versus ER-positive MCF7 cells (with wild-type p53) by confocal microscopy and flow cytometry. Depletion of mutant p53 reduced peptide uptake, confirming target specificity. In mice bearing xenografts, Cy5p53Tet was detectable in tumor tissue within 12 minutes of injection. Significantly higher uptake was observed in mutant p53-expressing TNBC tumors compared to wild-type p53 tumors.
Why it matters
TNBC is the only major breast cancer subtype with no targeted therapy or detection method. Mutant p53 is present in over 80% of TNBCs, making it an ideal target. This peptide approach could serve dual purposes: helping surgeons see exactly where the cancer is during surgery (fluorescence-guided surgery) and potentially delivering toxic payloads directly to cancer cells. Finding and treating TNBC more precisely could improve outcomes for this aggressive cancer.
How the study worked
Researchers designed Cy5p53Tet containing the p53 tetramerization domain sequence conjugated to Cy5 fluorophore. Direct peptide-protein interaction was confirmed by co-immunoprecipitation and glutaraldehyde cross-linking. Cellular uptake was measured by confocal microscopy and flow cytometry in TNBC (MDA-MB-468, mutant p53) and ER-positive (MCF7, wild-type p53) cells. Target specificity was tested by p53 depletion experiments. In vivo imaging was performed in mice bearing MDA-MB-468 and MCF7 xenografts.
What this study cannot tell us
Preclinical study in cell lines and mouse xenografts — human pharmacokinetics, biodistribution, and tumor-to-background ratios in clinical settings are unknown. The selectivity between mutant and wild-type p53 tumors was demonstrated but the absolute specificity in a patient (where both normal and cancerous tissues are present) needs validation. The 12-minute detection time is based on a mouse model — timing in humans may differ. No therapeutic efficacy was tested — only imaging. Peptide stability in human plasma was not assessed.
How to read the evidence
This is a preclinical proof-of-concept study with both in vitro and in vivo validation, including important specificity controls (wild-type vs. mutant p53 cells, p53 depletion). Published in Molecular Pharmaceutics, the methodology is rigorous. However, clinical translation requires human safety and imaging performance data.
When this study was published
Published in 2021, this study pioneered intracellular peptide-based targeting of mutant p53 for TNBC imaging. The concept of fluorescence-guided breast cancer surgery continues to advance in clinical trials.
The bigger picture
Peptide-based cancer imaging and targeting is a growing field that bridges diagnostics and therapeutics ('theranostics'). This study demonstrates that peptides can be designed to target intracellular proteins (not just surface receptors), entering the cell nucleus to interact with their target. The p53 tetramerization domain scaffold could be adapted to carry radionuclides for PET imaging, toxins for direct killing, or other payloads — making it a versatile platform for TNBC-specific medicine.
Questions still open
- Can Cy5p53Tet achieve sufficient tumor-to-background contrast for fluorescence-guided surgery in human patients?
- Could the peptide scaffold be modified to carry cytotoxic payloads for targeted TNBC therapy beyond imaging?
- Does the peptide distinguish TNBC from other cancers that also express mutant p53 (lung, ovarian, colorectal)?
Common questions
What is triple negative breast cancer and why is it so hard to treat?
How could this peptide help during breast cancer surgery?
Read the original research
Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
Molecular pharmaceutics, 18(1), 338-346
Citation
Xiao, Gu; Annor, George K; Fung, Kimberly; Keinänen, Outi; Zeglis, Brian M; Bargonetti, Jill. (2021). Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.. Molecular pharmaceutics, 18(1), 338-346. https://doi.org/10.1021/acs.molpharmaceut.0c00978